Absci Stock Jumps

AMD invests $20 million in AI drug research at Vancouver-based Absci
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial intelligence will enable it to move faster to develop protein-based medicines called biologics,
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
AMD to invest $20m in Absci to boost AI drug discovery tech
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design models.
AMD shadows NVIDIA with a move into AI drug discovery
The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug discovery workloads, including a biologic drug design platform using generative AI (genAI) that has attracted alliances with AstraZeneca, MSD, and Almirall.
AMD is going head-to-head with Nvidia in AI-backed drug discovery with new deal
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
AMD Invests in Absci to Strengthen AI Chip Presence in Drug Discovery
In a strategic move to expand its footprint in the healthcare sector, Advanced Micro Devices (AMD) has announced a $20 million investment in Absci, a Washington-based drug-discovery company. This investment not only highlights AMD’s ambition to diversify its market presence but also emphasizes the growing role of artificial intelligence (AI) in revolutionizing life sciences.
Absci stock soars on AMD partnership and investment
Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic collaboration and a $20 million investment from AMD (NASDAQ: AMD ). The partnership aims to enhance Absci's AI-driven drug discovery capabilities using AMD's Instinct accelerators and ROCm software.
Absci Announces Strategic Collaboration With AMD To Advance AI-Driven Drug Discovery
Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to
AbSci’s Strategic Growth Bolstered by AMD Collaboration and Promising Pipeline Advancements
Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...
AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced
Following HSBC downgrading of the semiconductor company's stock, Advanced Micro Devices ( AMD, Financials) shares fell over 5 ...
Absci rises after report on $20M investment by Advanced Micro Devices
Absci (NASDAQ:ABSI) was rising after a media report about the semiconductor company Advanced Micro Devices (NASDAQ:AMD) ...
Absci price target lowered to $5 from $6 at KeyBanc
KeyBanc lowered the firm’s price target on Absci (ABSI) to $5 from $6 and keeps an Overweight rating on the shares. The firm notes healthcare ...
bovnews5d
Uncover the Reason: Why Absci Corp (ABSI) Stock Is Trading 10.61% Above Its 52-Week Low?
On Thursday, Absci Corp (ABSI) stock saw a modest uptick, ending the day at $2.71 which represents a slight increase of $0.09 or 3.44% from the prior close of $2.62. The stock opened at $2.7 and ...
Absci Co. (NASDAQ:ABSI) Stock Holdings Lifted by Barclays PLC
Barclays PLC lifted its stake in shares of Absci Co. (NASDAQ:ABSI – Free Report) by 379.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 131,504 shares of the company’s stock after ...
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Absci has built a leading generative AI Drug Creation platform for therapeutic antibodies and we’re excited to bring this expertise into animal health,” said Sean McClain, Founder and CEO of Absci.